ethyl 7-amino-4-oxo-4H-1-benzopyran-2-carboxylate | 30192-21-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: ethyl 7-amino-4-oxo-4H-1-benzopyran-2-carboxylate
• 英文别名: ethyl 7-amino-4-oxo-4H-chromene-2-carboxylate；7-amino-4-oxo-4H-chromene-2-carboxylic acid ethyl ester；ethyl 7-amino-4-oxochromene-2-carboxylate
• CAS: 30192-21-3
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: CNWVQPJMIBPYKK-UHFFFAOYSA-N

物化性质

• 沸点：
  410.6±45.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 7-amino-4-oxo-4H-1-benzopyran-2-carboxylate 在 钯 resultant residue 、 乙酸乙酯 、 碳酸氢钠 、 magnesium sulfate 作用下， 以 乙醇 、 盐酸 为溶剂， 25.0 ℃ 、45.96 MPa 条件下， 反应 72.0h， 以to afford the title compound as an amber oil, 0.85 g (89% yield)的产率得到ethyl (R,S)-3,4-dihydro-7-amino-2H-1-benzopyran-2-carboxylate
  参考文献：
  名称：

  Chroman derivatives as 5-hydroxytrytamine-6 ligands

  摘要：

  本发明提供了一种I式化合物及其用于治疗与5-HT6受体相关或受其影响的疾病的用途。

  公开号：

  US20030158175A1
• 作为产物：
  描述：

  7-Acetylamino-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 ethyl 7-amino-4-oxo-4H-1-benzopyran-2-carboxylate
  参考文献：
  名称：

  New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D₂ Agonist Pharmacophore. Structure−Activity Relationships of a Series of 2-(Aminomethyl)chromans

  摘要：

  A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high-and low-affinity agonist states (D-2(High) and D-2(Low), respectively) of the dopamine (DA) D-2 receptor. The 7-hydroxy-2-(aminomethyl)chroman moiety was observed to be the primary D-2 agonist pharmacophore. The 2-methylchroman moiety was discovered to be an entirely novel scaffold which could be used to access the D-2 agonist pharmacophore. Attaching various simple alkyl and arylalkyl side chains to the 7-hydroxy 2-AMC nucleus had significant effects on selectivity for the D-2(High) receptor vs the 5HT(1A) and alpha(1) receptors. A novel DA partial agonist, (R)-(-)-2-(benzylamino)methyl)chroman-7-ol [R-(-)-35c], was identified as having the highest affinity and best selectivity for the D-2(High) receptor vs the alpha(1) and 5HT(1A) receptors. Several regions of the 2-AMC nucleus were modified and recognized as potential sites to modulate the level of intrinsic activity. The global minimum conformer of the 7-hydroxy-2-AMC moiety was identified as fulfilling the McDermed model D-2 agonist pharmacophoric criteria and was proposed as the D-2 receptor-bound conformation. Structure-activity relationships gained from these studies have aided in the synthesis of D-2 partial agonists of varying intrinsic activity levels. These agents should be of therapeutic value in treating disorders resulting from hypo-and hyperdopaminergic activity, without the side effects associated with complete D-2 agonism or antagonism.

  DOI：

  10.1021/jm9703653

文献信息

• Chroman-2-ylmethylamino derivatives
  申请人：——

  公开号：US05663194A1

  公开（公告）日：1997-09-02

  Described herein are compounds of the formula: ##STR1## in which n is 1, 2 or 3; m is 0 or 1; and R is a substituted or unsubstituted phenyl group in which the substitutents are, independently, one or two members selected from the group consisting of alkyl, hydroxy, halo or amino groups or R is alkyl of 1 to 6 carbon atoms or hydroxyalkyl of 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are inhibitors of dopamine synthesis and release, and are useful in the treatment of schizophrenia, Parkinson's Disease, Tourette's Syndrome, alcohol addiction, cocaine addiction, and addiction to analagous drugs.

  本文描述的是以下化合物：##STR1## 其中n为1、2或3；m为0或1；R为取代或未取代的苯基，其中取代基独立地为从烷基、羟基、卤素或氨基组成的一种或两种成员，或者R为1至6个碳原子的烷基或1至6个碳原子的羟基烷基；或其药学上可接受的盐，这些化合物是多巴胺合成和释放的抑制剂，可用于治疗精神分裂症、帕金森病、图雷特综合症、酒精成瘾、可卡因成瘾和类似药物成瘾。
• Pyranoquinolinones and analogs thereof
  申请人：Fisons Limited

  公开号：US04419352A1

  公开（公告）日：1983-12-06

  There are described compounds of formula I, ##STR1## in which an adjacent pair of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 form a chain --CZC(G.sub.1).dbd.(G.sub.2)--Z--, R.sub.4, R.sub.9 and the remainder of R.sub.5, R.sub.6, R.sub.7 and R.sub.8, which may be the same or different, each represent hydrogen, alkyl, halogen, alkenyl, --NO.sub.2, --NR.sub.1 R.sub.2, --OR.sub.3, --S(O).sub.n R.sub.3 ; or alkyl substituted by hydroxy, amino, alkoxy or carbonyl oxygen, n is 0, 1 or 2, R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen, alkyl, --CONHR.sub.3, phenyl or phenyl substituted by alkyl or halogen, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocyclic ring, R.sub.3 represents hydrogen, alkyl, alkenyl or phenyl, one of G.sub.1 and G.sub.2 is hydrogen and the other is a group E, each E, which may be the same or different, is --COOH, a 5-tetrazolyl group, or a carboxamidotetrazole group, each Z, which may be the same or different, is oxygen or sulphur, and one or two of the atoms, a, b, c and d are nitrogen atoms and the remainder are carbon atoms, R.sup.9 having no significance when two of a, b, c and d are nitrogen, (with certain exclusions) and pharmaceutically acceptable derivatives thereof. There are also described methods for making the compounds and pharmaceutical, e.g. anti-allergic, compositions and mixtures containing them.

  描述了具有I式化合物，其中相邻的R.sub.5、R.sub.6、R.sub.7和R.sub.8形成一个链--CZC(G.sub.1).dbd.(G.sub.2)--Z--，R.sub.4、R.sub.9和R.sub.5、R.sub.6、R.sub.7和R.sub.8的其余部分，它们可能相同也可能不同，分别代表氢、烷基、卤素、烯基、-NO.sub.2、-NR.sub.1 R.sub.2、-OR.sub.3、-S(O).sub.n R.sub.3；或被羟基、氨基、烷氧基或酰氧基取代的烷基，n为0、1或2，R.sub.1和R.sub.2，它们可能相同也可能不同，分别代表氢、烷基、-CONHR.sub.3、苯基或被烷基或卤素取代的苯基，或者R.sub.1和R.sub.2与它们连接的氮原子一起形成5或6元杂环环，R.sub.3代表氢、烷基、烯基或苯基，G.sub.1和G.sub.2中的一个是氢，另一个是E基团，每个E，可能相同也可能不同，是-羧基、5-四唑基团或羧酰氨基四唑基团，每个Z，可能相同也可能不同，是氧或硫，a、b、c和d中的一个或两个是氮原子，其余是碳原子，当a、b、c和d中两个是氮时，R.sup.9没有意义（具体排除了某些情况），以及其药用可接受的衍生物。还描述了制备这些化合物的方法以及含有它们的制药、例如抗过敏、组合物和混合物。
• Process for producing chromone compound
  申请人：Hibino Hiroaki

  公开号：US20050085664A1

  公开（公告）日：2005-04-21

  A process for producing a dicarboxylic acid compound represented by the formula (4): wherein R 1 and R 2 are the same or different and each represents lower alkyl and the wavy line indicates that this compound is the E- or Z-isomer or a mixture of them, characterized by reacting a compound represented by the formula (2): wherein R 1 , R 2 and the wavy line have the same meanings as the above, and one of X 2 and X 3 represents hydrogen and the other represents halogen, with nitrophenol represented by the formula (3): in the presence of a base; a process for producing a nitrochromone compound represented by the formula (5): wherein R 1 has the same meaning as the above, characterized by reacting the dicarboxylic acid compound or carboxylic acid thereof with an acid; a process for producing an aminochromone compound which comprises reducing the nitrochromone compound; and a process for producing an amidochromone compound which comprises acylating the aminochromone compound are provided.

  提供一种制备式（4）的二羧酸化合物的方法，其中R1和R2相同或不同，每个代表低级烷基，波浪线表示该化合物是E或Z异构体或它们的混合物，其特征在于将式（2）的化合物与硝基酚在碱的存在下反应，式中R1、R2和波浪线的含义与上述相同，X2和X3中的一个代表氢，另一个代表卤素；提供一种制备式（5）的硝基香豆素化合物的方法，其中R1的含义与上述相同，其特征在于将二羧酸化合物或其羧酸与酸反应；提供一种制备氨基香豆素化合物的方法，其包括还原硝基香豆素化合物；以及提供一种制备酰胺香豆素化合物的方法，其包括酰化氨基香豆素化合物。
• Chroman derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Wyeth

  公开号：US06706757B2

  公开（公告）日：2004-03-16

  The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

  本发明提供了一种式I的化合物以及其在治疗与或受5-HT6受体影响的疾病方面的应用。
• PROCESS FOR PRODUCING CHROMONE COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1479667A1

  公开（公告）日：2004-11-24

  A process for producing a dicarboxylic acid compound represented by the formula (4): wherein R1 and R2 are the same or different and each represents lower alkyl and the wavy line indicates that this compound is the E- or Z-isomer or a mixture of them, characterized by reacting a compound represented by the formula (2): wherein R1, R2 and the wavy line have the same meanings as the above, and one of X2 and X3 represents hydrogen and the other represents halogen, with nitrophenol represented by the formula (3): in the presence of a base; a process for producing a nitrochromone compound represented by the formula (5): wherein R1 has the same meaning as the above, characterized by reacting the dicarboxylic acid compound or carboxylic acid thereof with an acid; a process for producing an aminochromone compound which comprises reducing the nitrochromone compound; and a process for producing an amidochromone compound which comprises acylating the aminochromone compound are provided.

  一种生产由式(4)代表的二羧酸化合物的工艺： 其中 R1 和 R2 相同或不同，且各自代表低级烷基，波浪线表示该化合物为 E-或 Z-异构体或它们的混合物，其特征在于使式（2）所代表的化合物反应： 其中 R1、R2 和波浪线的含义与上述相同，X2 和 X3 中的一个代表氢，另一个代表卤素： 在碱存在下；生产式（5）代表的硝基色酮化合物的工艺： 其中 R1 的含义与上述相同，其特征在于使二羧酸化合物或其羧酸与酸反应；提供了一种生产氨基色素化合物的工艺，该工艺包括还原硝基色素化合物；以及一种生产氨基色素化合物的工艺，该工艺包括酰化氨基色素化合物。